Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic promoters to induce immune-effectors into the tumor microenvironment

29 Jan 2021

Abstract excerpt

Harnessing the immune-system to eradicate cancer is becoming a reality in recent years. Engineered immune cells, such as chimeric antigen receptor (CAR) T cells, are facing the danger of an overt life-threatening immune response due to the ON-target OFF-tumor cytotoxicity and Cytokine Release Syndrome. We therefore developed synthetic promoters for regulation of gene expression under the control of inflammation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33514819
DOI: 10.1038/s42003-021-01664-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic promoters to induce immune-effectors into the tumor microenvironmentPMID 33514819Read ↗

Design of novel synthetic promoters to tune gene expression in T cellsSemantic proximity Read ↗

Sense-and-respond payload delivery using a novel antigen-inducible promoter improves suboptimal CAR-T activationSemantic proximity Read ↗

The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor MicroenvironmentSemantic proximity Read ↗

Regulation of CAR transgene expression to design semiautonomous CAR-TSemantic proximity Read ↗

Significant Advancements and Evolutions in Chimeric Antigen Receptor DesignSemantic proximity Read ↗

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomasSemantic proximity Read ↗

Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian CellsSemantic proximity Read ↗

<i>First-in-class</i> Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomasSemantic proximity Read ↗

Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factorSemantic proximity Read ↗

In Situ Reprogramming of Immune Cells Using Synthetic NanomaterialsSemantic proximity Read ↗

Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacySemantic proximity Read ↗

Scarless circular mRNA-based CAR-T cell therapy elicits superior anti-tumor efficacySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.